Trelegy Ellipta filing accepted by EMA for asthma
As it stands there is no single inhaled triple therapy available for the treatment of asthma in Europe.
Read Moreby Anna Smith | Feb 28, 2020 | News | 0
As it stands there is no single inhaled triple therapy available for the treatment of asthma in Europe.
Read Moreby Anna Smith | May 7, 2019 | News | 0
The companies had entered into an agreement in 2010 under which GSK had taken a license to formulation technology covered by a Vectura patent family.
Read Moreby Selina McKee | Nov 9, 2018 | News | 0
Hikma Pharmaceuticals and Vectura have signed a deal to develop and market generic versions of GlaxoSmithKline’s Ellipta portfolio, utilising the latter’s Open-Inhale-Close dry powder inhaler device.
Read Moreby Selina McKee | Feb 8, 2018 | News | 0
GlaxoSmithKline has reported a sales hike of 3 percent at constant exchange rates (CER*) for 2017, after growth was recorded across all of its three global businesses.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
